CN1157138A - 一种以文蛤提取物为主要药物成分的口服液及其生产方法 - Google Patents
一种以文蛤提取物为主要药物成分的口服液及其生产方法 Download PDFInfo
- Publication number
- CN1157138A CN1157138A CN96115663.5A CN96115663A CN1157138A CN 1157138 A CN1157138 A CN 1157138A CN 96115663 A CN96115663 A CN 96115663A CN 1157138 A CN1157138 A CN 1157138A
- Authority
- CN
- China
- Prior art keywords
- oral liquid
- clam extract
- clam
- extract
- deionized water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000284 extract Substances 0.000 title claims abstract description 38
- 239000007788 liquid Substances 0.000 title claims abstract description 20
- 241001262059 Meretrix Species 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- 239000008367 deionised water Substances 0.000 claims abstract description 9
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 7
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 7
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 7
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 7
- 238000004519 manufacturing process Methods 0.000 claims abstract description 6
- 108010010803 Gelatin Proteins 0.000 claims abstract description 5
- 229920000159 gelatin Polymers 0.000 claims abstract description 5
- 239000008273 gelatin Substances 0.000 claims abstract description 5
- 235000019322 gelatine Nutrition 0.000 claims abstract description 5
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 4
- 238000005360 mashing Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 5
- 238000011282 treatment Methods 0.000 abstract description 5
- 238000002512 chemotherapy Methods 0.000 abstract description 4
- 238000000034 method Methods 0.000 abstract description 3
- 230000004614 tumor growth Effects 0.000 abstract description 3
- 230000036039 immunity Effects 0.000 abstract description 2
- 210000000265 leukocyte Anatomy 0.000 abstract description 2
- 230000008569 process Effects 0.000 abstract description 2
- 108091005461 Nucleic proteins Proteins 0.000 abstract 1
- 235000012907 honey Nutrition 0.000 abstract 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 9
- 235000013372 meat Nutrition 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 6
- 230000036528 appetite Effects 0.000 description 6
- 235000019789 appetite Nutrition 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 229960004397 cyclophosphamide Drugs 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 230000000292 leukogenic effect Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 229930192392 Mitomycin Natural products 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 201000002364 leukopenia Diseases 0.000 description 2
- 231100001022 leukopenia Toxicity 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 235000015170 shellfish Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000011521 systemic chemotherapy Methods 0.000 description 2
- 229930195573 Amycin Natural products 0.000 description 1
- 235000010894 Artemisia argyi Nutrition 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000006268 Sarcoma 180 Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 244000030166 artemisia Species 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- GTBYFJITPRWOBT-UHFFFAOYSA-N diethyl 1,4-dihydroxynaphthalene-2,3-dicarboxylate Chemical compound C1=CC=C2C(O)=C(C(=O)OCC)C(C(=O)OCC)=C(O)C2=C1 GTBYFJITPRWOBT-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 201000004637 gastric cardia carcinoma Diseases 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 229940040511 liver extract Drugs 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G11—INFORMATION STORAGE
- G11B—INFORMATION STORAGE BASED ON RELATIVE MOVEMENT BETWEEN RECORD CARRIER AND TRANSDUCER
- G11B21/00—Head arrangements not specific to the method of recording or reproducing
- G11B21/02—Driving or moving of heads
- G11B21/08—Track changing or selecting during transducing operation
Landscapes
- Moving Of Head For Track Selection And Changing (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Moving Of The Head For Recording And Reproducing By Optical Means (AREA)
Abstract
本发明提供了一种以文蛤提取物为主要药物成分的口服液及其生产方法,文蛤提取物中含有文蛤核酸、蛋白质及少量糖分,该口服液的成分为文蛤提取物、明胶、蜂蜜、无离子水,这种口服液服用方便,治疗效果好,能有效抑制肿瘤生长,对化疗过程中的白细胞减少有显著的升白作用,能提高机体免疫力。
Description
本发明提供了一种以海洋贝类活性物质文蛤提取物为主要药物成份的口服液及其生产方法。
文蛤是产于沿海的贝类海洋生物。现代研究表明,文蛤肉中含有多种氨基酸、维生素及微量元素。由于文蛤肉不易保存,运输困难,目前只作食品使用,限制了该资源的开发,未能充分发挥文蛤肉的医疗保健作用。文蛤肉中含有的文蛤核酸(MNA)是具有抗肿瘤、升白作用的药理活性物质。《中国药用海洋生物》记载,文蛤组织液有抑菌作用,蛤肝提取物对染有Monloeg白血病毒的动物,使其存活期延长。组织提取液对肉瘤180的抑制率在30%以上,对艾瘤腹水型抑制率达96.1~262.5%以上,对肝癌腹水型和肝癌实体型的抑型率分别在40%和50%以上。有人曾以盐析及色谱层析分离提取文蛤肉中的蛋白质,虽证明其提取物具有抗肿瘤作用,但因其有致敏作用,故未能形成产品用于癌症病人治疗。还有人曾将文蛤肉水解,研究了其免疫作用,但未进一步分离提取,难以制成易于保存、服用方便的产品。
本发明的目的是提供一种以文蛤提取物为主要药物成份的口服液及其生产方法,以充分发挥文蛤肉内活性物质即文蛤提取物的药物治疗作用。
本发明是这样实现的,一种以文蛤提取物为主要药物成份的口服液,文蛤提取物中含有文蛤核酸30-40%,蛋白质8-16%,糖小于1%,该口服液的成份及含量分别为:文蛤提取物100g,明胶190-210g,蜂蜜900-1100ml,无离子水补至所有成份总量10000ml。
一种以文蛤提取物为主要药物成份的口服液的制造方法,文蛤提取物中含有文蛤核酸30-40%,蛋白质8-16%,糖小于1%,取文蛤提取物100g溶于200ml无离子水中,用组织捣碎机进行捣碎2分钟,然后加热溶解备用,取明胶190-210g加无离子水2000ml浸泡20分钟后,加热溶解备用,合并上述两溶液后加蜂蜜900-1100ml,混合后,用无离子水补至所有成份总量10000ml,过滤,灌装,100℃温度灭菌30分钟,即可制得口服液。
这种以文蛤提取物为主要药物成份的口服液,服用方便,治疗效果好,能有效抑制肿瘤生长,对化疗过程中的白细胞减少有显著的升白作用,能提高机体免疫力。
本发明所用的文蛤提取物是取文蛤肉绞碎匀浆,加入苯酚,提取离心后加入乙醇沉淀,并用乙醚洗去苯酚,晾干而得到的。
通过对上述文蛤提取物(其中含文蛤核酸30-40%,蛋白质8-16%,糖小于1%)的药理研究表明,文蛤提取物可有效抑制动物(以小鼠为实验动物)肿瘤生长,延长白血病动物存活时间,对环磷酰胺所致白细胞下降有显著的升白作用。
以下为文蛤提取物几种药理实验结果的统计表。
表1 文蛤提取物对Lewis肺癌动物瘤重的影响
项 目 体 重(克) 平均瘤重 抑制率P值组 别 给药前 给药后 克 (%) |
空白对照 22.6±1.1 20.3±1.6 2.1±0.5环磷酰胺(60mg/kg) 23.2±1.2 19.3±0.7 0.6±0.3 66%文蛤提取物(100mg/kg) 23.3±1.6 19.4±1.4 1.8±0.6 14%文蛤提取物(200mg/kg) 23.7±1.8 19.8±1.5 1.3±0.8 38% ∠0.05 |
表2 文蛤提取物对P388白血病小鼠生存时间的影响
项 目 体 重(克) 平均生存 生命延长率P值组 别 给药前 给药后 天数 (%) |
空白对照 18.3±1.2 25.5±1.8 12.8±3.1环磷酰胺(60mg/kg) 18.3±1.0 18.2±1.3 15.8±5.2 +3天23.4% ∠0.05文蛤提取物(100mg/kg) 18.6±1.2 23.9±1.7 13.1±2.6 +0.3天文蛤提取物(200mg/kg) 18.6±1.1 19.4±1.2 16.8±4.1 +4天31% ∠0.05 |
表3 文蛤提取物对环磷酰胺致小鼠白细胞减少的影响
WBLY/mm 变化率组 别 nx±SD % |
对 照 10 6005±791.8环磷酰胺 9 2500±561.2 -58.4环磷酰胺+茜草双酯 11 3291±991.2 +51.6环磷酰胺+文蛤提取物小剂量10 3515±1050.9 +40.6环磷酰胺+文蛤提取物小剂量10 3155±1144.7 +26.2 |
通过实验还表明,文蛤提取物能显著促进动物免疫器官的发育成熟,促进抗体形成白细胞的形成,促进抗体的生成,提高淋巴细胞转化率,能促进白介素-2的产生,具有免疫调节作用,对血循环免疫复合物物形成无影响。
下面提供了利用本发明之口服液进行治疗的实施例。
实施例1
杜××,男,39岁,因进行性吞咽困难入院,入院诊断,贲门癌。予丝裂霉素、顺铂(DDP),5-氟脲嘧啶(5-FU)、阿霉素(ADM)四药联合全身化疗。用药结束10天后,食欲仍低,恶心明显,心悸,乏力感较著,无头晕,不发热,复查血,WBC3.5×109/LN76% L24%尿常规,肝、肾功能均正常,免疫球蛋白正常范围,即予口服液20ml,Bid4天后,食欲明显增加,恶心消失,心悸及乏力感明显减轻,7天后复查血WBC5.5×109/L,N74%,14天后上述症状均消失,食欲较化疗前好,血WBC5.5×109/L,N54%,21天后,血WBC8.5×109/L,N68%,L32%,14天、21天时复查尿常规,肝、肾功能及免疫指标均正常,且期间无不良反应,21天后行全身化疗一周期,用药为丝裂霉素、5-Fu、ADM至结束,血象及各项检查均正常。
实施例2
马××,男,61岁,因右肋隐痛、纳差、消瘦、腹胀1个月,诊断肝癌,服用FT-207,0.2克,一日三次,症状未减轻,且出现恶心、呕吐,化验GPT67u,rGT234u,AFP780ug/ml,WBC3.8×109/L,给予该口服液20ml口服,Bid共21天,症状明显改善,仍有纳差、消瘦,化验肝功rGT正常范围,AFP400ug/ml,WBC4.2×109/L。
实施例3
王××,女,64岁,晚期肺癌,经环磷酰胺、顺铂、长春新碱化疗一个疗程后,白细胞降至3.4×109/L,且伴乏力、食差、恶心等症状,经口服该口服液20ml,Bid21天后,乏力减轻,食欲改善、恶心消失,复查WBC6.1×109/L,淋巴细胞亚群治疗前T4/T8=30/54,治疗后T4/T8=47/30,辅助性T细胞升高,抑制性T淋巴细胞降低,比值恢复正常,说明病人的细胞免疫有所恢复。
Claims (2)
1、一种以文蛤提取物为主要药物成份的口服液,其特征在于,所述的文蛤提取物中含有文蛤核酸30-40%,蛋白质8-16%,糖小于1%,该口服液的成份及含量分别为:文蛤提取物100g,明胶190-210g,蜂蜜900-1100ml,无离子水补至所有成份总量10000ml。
2、一种以文蛤提取物为主要药物成份的口服液的生产方法,其特征在于,所述的文蛤提取物中含有文蛤核酸30-40%,蛋白质8-16%,糖小于1%,取文蛤提取物100g溶于200ml无离子水中,用组织捣碎机进行捣碎2分钟,然后加热溶解备用,取明胶190-210g加无离子水2000ml浸泡20分钟后,加热溶解备用,合并上述两溶液后加蜂蜜900-1100ml,混合后,无离子水补至所有成份总量10000ml,过滤,灌装,100℃温度灭菌30分钟,即可制得口服液。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP9178337A JPH1125622A (ja) | 1997-07-03 | 1997-07-03 | スレッド移動方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1157138A true CN1157138A (zh) | 1997-08-20 |
Family
ID=16046734
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN96115663.5A Pending CN1157138A (zh) | 1997-07-03 | 1996-02-12 | 一种以文蛤提取物为主要药物成分的口服液及其生产方法 |
CN98115663.0A Expired - Fee Related CN1127723C (zh) | 1997-07-03 | 1998-07-03 | 盘装置和用于此目的的线程移动方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN98115663.0A Expired - Fee Related CN1127723C (zh) | 1997-07-03 | 1998-07-03 | 盘装置和用于此目的的线程移动方法 |
Country Status (3)
Country | Link |
---|---|
US (1) | US6064633A (zh) |
JP (1) | JPH1125622A (zh) |
CN (2) | CN1157138A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107252412A (zh) * | 2017-06-27 | 2017-10-17 | 缪来耿 | 一种消炎杀菌牙膏及其制备方法 |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000207824A (ja) * | 1999-01-07 | 2000-07-28 | Funai Electric Co Ltd | ディスクドライブ装置 |
JP4158262B2 (ja) * | 1999-02-26 | 2008-10-01 | ソニー株式会社 | 情報記録再生装置および方法ならびに記録媒体 |
US6356528B1 (en) * | 1999-04-15 | 2002-03-12 | Qualcomm Incorporated | Interleaver and deinterleaver for use in a diversity transmission communication system |
US6445650B1 (en) * | 2000-05-02 | 2002-09-03 | Discovision Associates | High-speed dynamic actuating system for optical disks |
JP2002245640A (ja) * | 2001-02-15 | 2002-08-30 | Funai Electric Co Ltd | 光ディスク装置 |
US9473052B2 (en) | 2012-03-12 | 2016-10-18 | Panasonic Intellectual Property Management Co., Ltd. | Motor drive method and motor drive device |
JP6295189B2 (ja) * | 2014-11-28 | 2018-03-14 | 株式会社日立製作所 | エレベータ装置 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63269324A (ja) * | 1987-04-28 | 1988-11-07 | Mitsubishi Electric Corp | 光デイスク駆動装置 |
JPH07296393A (ja) * | 1994-04-22 | 1995-11-10 | Nippon Conlux Co Ltd | 光学的情報記録再生方法及び装置 |
US5623464A (en) * | 1994-09-29 | 1997-04-22 | Fujitsu Limited | Optical disk apparatus and seek control method |
-
1996
- 1996-02-12 CN CN96115663.5A patent/CN1157138A/zh active Pending
-
1997
- 1997-07-03 JP JP9178337A patent/JPH1125622A/ja active Pending
-
1998
- 1998-06-29 US US09/107,176 patent/US6064633A/en not_active Expired - Lifetime
- 1998-07-03 CN CN98115663.0A patent/CN1127723C/zh not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107252412A (zh) * | 2017-06-27 | 2017-10-17 | 缪来耿 | 一种消炎杀菌牙膏及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
US6064633A (en) | 2000-05-16 |
JPH1125622A (ja) | 1999-01-29 |
CN1127723C (zh) | 2003-11-12 |
CN1204838A (zh) | 1999-01-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20080206375A1 (en) | Composition of Radix Codonopsis and Radix Astragali, a Method for Preparation Thereof and its Application | |
CN107441078A (zh) | 一种治疗糖尿病的药物组合物及其制备方法和用途 | |
CN109939143A (zh) | 一种用于降血糖控制并发症的中药组合物及其制备方法 | |
CN1157138A (zh) | 一种以文蛤提取物为主要药物成分的口服液及其生产方法 | |
CN103735937B (zh) | 具有促进铁成分吸收并且补血的药物及保健品 | |
CN115120689A (zh) | 欣力康复方制剂在制备药物中的应用 | |
CN105596994A (zh) | 用于治疗肺癌细胞增殖的药物 | |
CN103622027B (zh) | 一种降血糖保健食品组合物 | |
CN1063047C (zh) | 一种以文蛤提取物为药物成分的胶囊及其生产方法 | |
EP0246069B1 (en) | Extracts of nerium species, methods of preparation, and use therefore | |
Malmros | A study of glycosuria: With special reference to the interpretation of the incidental finding of a positive reduction test | |
CN1368979A (zh) | 造血的阿拉伯半乳聚糖组合物 | |
CN1397567A (zh) | 螺旋藻多糖及其提取方法和在制备升白和抗癌药物中的用途 | |
KR100506950B1 (ko) | 진세노사이드를 함유함을 특징으로 하는 면역증강효과에 대한 조성물 | |
CN102224931A (zh) | 一种辅助降血糖的组合物 | |
CN112494502A (zh) | 一种用于血虚证补血的糖类组合物 | |
CN101053588A (zh) | 一种复方阿拉伯半乳聚糖薄膜衣片的制备方法 | |
Calleja et al. | Acute hepatitis treated with high doses of vitamin C | |
CN103719661A (zh) | 补血口服液保健品 | |
CN104306895A (zh) | 一种治疗代偿期肝硬化的药物 | |
CN103908610A (zh) | 一种降低结直肠癌术后复发转移的中药复方制剂及其制备方法 | |
CN116920066B (zh) | 一种治疗肺结节及肺癌的中药组合物及其制剂和应用 | |
CN110404021A (zh) | 一种黄精制剂及制备方法 | |
KR101985965B1 (ko) | 복합 생약 추출물을 유효성분으로 함유하는, 시스플라틴에 의한 부작용 예방, 개선 또는 치료용 약학적 조성물 | |
CN110876802B (zh) | 一种抗癌症的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |